Groningen, The Netherlands, 8 June 2017 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it has signed agreements with leading medical technology distributors in Europe, to meet the growing distribution demands for Polyganics’ Peripheral Nerve Repair (PNR) products.

Orthomed is an experienced PNR distributor in France that will provide Polyganics’ products to their established clinical network. Tapmed will take charge of the distribution in Germany, Austria and Switzerland whilst and Osteotec will look after the UK distribution. The new distributors will join the broad European network already in place. Amongst others, the existing distributors include, JB-Implants (The Netherlands), Medcomtech (Spain and Portugal), DMR (Italy), Next Medical (Italy) and Swemac (Denmark and Sweden).

NEUROCAP®, launched in 2016, created a novel dedicated treatment option for the treatment of end-neuromas and has completed Polyganics’ PNR product portfolio. The combination of a purely synthetic and transparent polymer with an extensive proven safety and efficacy record is unique in the PNR medical device market. Alternatives for peripheral nerve injury treatment tend to require either complex surgical procedures or material of human or animal origin. Polyganics’ PNR product range offers surgeons a complete toolbox to support their surgical procedures and to provide optimal care for their patients.

Rudy Mareel, CEO of Polyganics said: “Our reinforced PNR focus has resulted in a unique product portfolio that has been acknowledged by highly reputable medical centres, with the clinical community recognizing the benefits of our PNR products. We have initiated multiple clinical trials including post marketing studies to show the positive effects our portfolio has on symptomatic end neuroma pain. The appointment of new distributors enables us to meet the growing demand in Europe and simultaneously prepare for further growth in this market.”

Bruno Deguzman of Orthomed said: “We provide products to a vast network of physicians and we look forward to maintaining our market leading position in France with the addition of Polyganics’ PNR portfolio.”

Bill Stringer of Osteotec said: “Neurolac and Neurocap are being used in trials in The Queen Elizabeth University Hospital Birmingham. We are looking forward to serve additional clinical centers in the UK with Polyganics’ PNR products.”

Monika Rinne of Tapmed commented: “With our reach in Germany, Austria and Switzerland, we provide the best medical technology to the hospitals that we work with. We choose the right products for our clients and Polyganics’ PNR products will complement our current portfolio.”

About Polyganics

Polyganics is a medical technology company with multiple versatile polymer platforms. The Company develops, manufactures and commercializes innovative bioresorbable medical devices that facilitate tissue repair and regeneration.

Polyganics’ portfolio includes products developed in-house and in collaboration with leading medical technology companies and academic centers of excellence. In the Peripheral Nerve Repair (PNR) and neurosurgery field, the portfolio includes three marketed products: VIVOSORB® for minimizing unwanted tissue adhesions after surgery; NEUROLAC® for supporting PNR following hand surgery; and NEUROCAP® for the management of symptomatic neuromas. Products in development include a sealant for the dura membrane, for use post brain surgery.

In 2014, Polyganics sold its Ear, Nose & Throat (ENT) surgery business unit (the NASOPORE® product family including NASPORE FD®, HEMOPORE®, and OTOPORE®) to US Company Stryker, one of the world’s leading medical technology companies. NASOPORE®, a reliable, easy-to-use, nasal wound care dressing made of biodegradable foam, has been used in over 3.5m procedures globally. Polyganics continues to manufacture the NASOPORE® product range for Stryker.

Polyganics is profitable and privately held. The Company is based in Groningen, The Netherlands, a center of biomedical engineering excellence, in an ISO 13485-certified manufacturing facility. The Company’s polymer platform technologies are protected by a broad portfolio of patents and its products have received clearance from the US FDA, CE-approval, and approval from CFDA and other international authorities.

For more information, visit: www.polyganics.com